Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 Sep;48(3):395–403. doi: 10.1038/bjc.1983.204

Role of "lymphotoxin" in the local anti-tumour action associated with inflammation caused by delayed hypersensitivity responses or intralesional BCG. I. Variations in response of different syngeneic mouse tumours.

I B Parr, L E Jackson, P Alexander
PMCID: PMC2011480  PMID: 6604535

Abstract

The anti-tumour effect induced by a delayed hypersensitivity response (DHSR) unrelated to the tumour or by intra-tumoural inoculation of BCG was studied with 6 syngeneic mouse tumours. The growth of the tumours was followed i.p. or s.c. in suitably sensitized animals either in the presence or absence of the specific antigen required to elicit a DHSR. In a Winn-type assay the growth of tumour cells admixed with sensitized lymphocytes was also determined with and without the eliciting antigens. In addition, the effect of admixing different amounts of BCG with the tumour cells was studied on the growth of the tumours in vivo. The different tumours varied widely in their susceptibility to growth inhibition by a DHSR reaction and by BCG but their order of sensitivity was the same in all of the tests. Analysis of the effector population in the Winn test coupled with the inability to observe an anti-tumour action in mice with defective T-cell function showed that the effector mechanism involved allergized T-cells or more probably products released when these were confronted with the specific antigen. In vitro the relative susceptibility of the different tumour cells to killing by activated macrophages and by NK cells was quite different to that found for in vivo growth inhibition but the in vitro response to lymphotoxin of the different tumours paralleled that produced by inflammation in vivo.

Full text

PDF
395

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander P. Activated macrophages and the antitumor action of BCG. Natl Cancer Inst Monogr. 1973 Dec;39:127–133. [PubMed] [Google Scholar]
  2. Alexander P., Parr I. B., Jackson L. E. Mechanism of the local antitumor action of inflammation. Transplant Proc. 1981 Dec;13(4):1929–1931. [PubMed] [Google Scholar]
  3. Baldwin R. W., Pimm M. V. Influence of BCG infection on growth of 3-methylcholanthrene-induced rat sarcomas. Rev Eur Etud Clin Biol. 1971 Nov;16(9):875–881. [PubMed] [Google Scholar]
  4. Chung E. B., Zbar B., Rapp H. J. Tumor regression mediated by Mycobacterium bovis (strain BCG). Effects of isonicotinic acid hydrazide, cortisone acetate, and antithymocyte serum. J Natl Cancer Inst. 1973 Jul;51(1):241–250. doi: 10.1093/jnci/51.1.241. [DOI] [PubMed] [Google Scholar]
  5. Evans R., Cox H., Alexander P. Immunologically specific activation of macrophages armed with the specific macrophage arming factor (SMAF). Proc Soc Exp Biol Med. 1973 May;143(1):256–259. doi: 10.3181/00379727-143-37298. [DOI] [PubMed] [Google Scholar]
  6. Granger G. A., Kolb W. P. Lymphocyte in vitro cytotoxicity: mechanisms of immune and non-immune small lymphocyte mediated target L cell destruction. J Immunol. 1968 Jul;101(1):111–120. [PubMed] [Google Scholar]
  7. Hunter-Craig I., Newton K. A., Westbury G., Lacey B. W. Use of vaccinia virus in the treatment of metastatic malignant melanoma. Br Med J. 1970 May 30;2(5708):512–515. doi: 10.1136/bmj.2.5708.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Klein E. Tumors of the skin. X. Immunotherapy of cutaneous and mucosal neoplasms. N Y State J Med. 1968 Apr 1;68(7):900–911. [PubMed] [Google Scholar]
  9. Morton D., Eilber F. R., Malmgren R. A., Wood W. C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970 Jul;68(1):158–164. [PubMed] [Google Scholar]
  10. Parr I. B., Wheeler E., Alexander P. Selective mobilization of specifically cytotoxic T-lymphocytes at sites of inflammation in relation to BCG-induced resistance to implants of syngeneic sarcoma in mice. J Natl Cancer Inst. 1977 Dec;59(6):1659–1666. doi: 10.1093/jnci/59.6.1659. [DOI] [PubMed] [Google Scholar]
  11. Parr I. B., Wheeler L. E., Alexander P. Rejection of sarcoma cells at the site of an inflammatory reaction: macrophages are not the only effector cells. Cancer Lett. 1975 Sep;1(1):49–53. doi: 10.1016/s0304-3835(75)95094-6. [DOI] [PubMed] [Google Scholar]
  12. Parr I., Wheeler E., Alexander P. Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA. Br J Cancer. 1973 May;27(5):370–389. doi: 10.1038/bjc.1973.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. WINN H. J. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol. 1961 Feb;86:228–239. [PubMed] [Google Scholar]
  14. Wolfe S. A., Tracey D. E., Henney C. S. Introduction of "natural" killer' cells by BCG. Nature. 1976 Aug 12;262(5569):584–586. doi: 10.1038/262584a0. [DOI] [PubMed] [Google Scholar]
  15. Zbar B., Tanaka T. Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science. 1971 Apr 16;172(3980):271–273. doi: 10.1126/science.172.3980.271. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES